Hairfollicle stem cells remain in bald individuals, but progenitor cells do not, raising questions about hair regrowth claims by Pelage. PP405 is discussed as a potential treatment, with skepticism about its effectiveness compared to existing treatments like Minoxidil and Finasteride.
PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hairfollicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.
High DHEA levels may contribute to hair loss by increasing DHT in hairfollicles, potentially explaining why finasteride is ineffective for some. Treatments like high-dose dutasteride and RU58841 are suggested, but the underlying cause, such as adrenal issues, should be investigated.
Scalp tension potentially affecting hair loss, and potential treatments for male pattern baldness such as Minoxidil, Finasteride and RU58841. Evidence from a study was discussed which suggests that the cause of MPB lies within the follicle itself and is not dependent on its surrounding environment.
The conversation suggests that people should consult a dermatologist to understand their type of hair loss before starting treatments like finasteride or dutasteride, especially if they have autoimmune issues or low DHT. Some participants believe in starting treatment like finasteride immediately if hair loss is due to DHT, while others recommend ruling out other causes and considering minoxidil first, especially for younger individuals.